Winel Fonbah: Elevating Anticoagulation Literacy
Winel Fonbah, Registered Nurse at Regional hospital limbe, shared a post on LinkedIn:
“Elevating Anticoagulation Literacy: A Must-Know Guide for Clinicians!
Navigating the landscape of anticoagulants is fundamental for patient safety and effective treatment of conditions like AFib, DVT, and PE. I came across this excellent breakdown (shared below) and wanted to add some crucial context and clinical insights for my fellow healthcare professionals.
Anticoagulants: The Unsung Heroes of Cardiovascular Care.
In healthcare, few medication classes have as much impact on patient safety as anticoagulants, meds that prevent existing blood clots from getting bigger and stop new ones from forming.
While we often focus on the big names—Heparin, Warfarin (Coumadin), and newer Direct Oral Anticoagulants (DOACs)—what’s equally important is understanding how they differ, how they’re monitored, and how we keep patients safe.
Key Insights:
- Heparin: Fast-acting, short-term therapy; requires aPTT monitoring and has an antidote (Protamine sulfate). Watch for heparin-induced thrombocytopenia.
- Warfarin: Long-term therapy that needs consistent Vitamin K intake and regular INR monitoring, It has a slower onset, with antidotes including Vitamin K and FFP.
- DOACs: A newer class offering long-term protection with fewer monitoring requirements and fewer food interactions. Recently, more antidotes have been approved—making them even safer.
Across all anticoagulants, bleeding precautions remain essential, from avoiding aspirin to using soft toothbrushes and minimizing invasive procedures.
As clinicians, educators, or healthcare leaders, staying updated on these meds isn’t just knowledge—it’s patient safety.
Question for you:
- What’s one insight or tip you think every new nurse or healthcare student should know about anticoagulants?
Drop it in the comments—let’s build a resource together.”

Stay informed with Hemostasis Today.
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study
-
Nov 29, 2025, 16:42Dr Abdul Mannan on the Echinocyte: Mastering the Diagnostic Duality of Artifact vs. Pathology
-
Nov 29, 2025, 16:42Vikas Dua: Heme Next 1.0 A Conference with a Difference
-
Nov 29, 2025, 16:41Hind Ali: Sources Of Error in Cell Counts
-
Nov 29, 2025, 16:40Maxime Dely: Even on a Break, You Can Give
-
Nov 29, 2025, 16:39Shrinidhi Nathany: HemeNext Brings Science, Technology, and Leadership Together
-
Nov 29, 2025, 16:38PF4 Antibody Persistence and Long-term Pathogenicity in VITT
